Shares of Transenterix Inc (NASDAQ:TRXC) have earned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Transenterix’s rating score has improved by 16.5% from three months ago as a result of a number of analysts’ ratings changes.

Brokerages have set a 1 year consensus price target of $3.38 for the company and are predicting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned Transenterix an industry rank of 88 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research lowered shares of Transenterix from a “buy” rating to a “sell” rating in a research report on Tuesday, August 8th.

Shares of Transenterix (TRXC) traded up 3.50% on Friday, hitting $1.48. 1,922,536 shares of the stock were exchanged. The stock’s market cap is $219.83 million. The stock’s 50-day moving average is $0.86 and its 200-day moving average is $0.84. Transenterix has a 1-year low of $0.45 and a 1-year high of $2.33.

A number of institutional investors and hedge funds have recently made changes to their positions in TRXC. LMR Partners LLP purchased a new stake in Transenterix in the second quarter valued at approximately $189,000. Global X Management Co. LLC grew its position in Transenterix by 238.3% during the second quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock valued at $235,000 after acquiring an additional 233,213 shares during the last quarter. Royal Bank of Canada grew its position in Transenterix by 17.1% during the second quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock valued at $298,000 after acquiring an additional 61,034 shares during the last quarter. UBS Oconnor LLC bought a new position in Transenterix during the second quarter valued at approximately $390,000. Finally, Goldman Sachs Group Inc. grew its position in Transenterix by 7,137.7% during the second quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock valued at $854,000 after acquiring an additional 1,186,575 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Transenterix Inc (TRXC) to Announce ($0.09) EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/16/brokerages-expect-transenterix-inc-trxc-to-announce-0-09-eps.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.